Enveric Biosciences, Inc.
ENVBNASDAQHealthcareBiotechnology
Previous close
$1.43
+$0.04 · +2.88%
ENVB company overview
Historical prices · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
45
Fair Value
Momentum
17
Strong Down
Sentiment
66
Bullish
Risk resilience
30
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteEnveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Joseph Edward Tucker
- Listed since
- May 4, 2015
- Employees
- 6
Market position
Day range
Current $1.43
52-week range
Current $1.43
- Open
- $1.40
- Previous close
- $1.39
- Volume
- 89.15K
- 0.44× average
- Average volume
- 203.54K
- Average daily volume
- Market cap
- 853.73K USD
- Beta
- 1.11
- Market reference 1
- 50-day average
- $1.4209
- +0.64% above average
- 200-day average
- $2.9655
- -51.78% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -3.46M USD
- P/E (TTM)
- -0.09×
- P/B (TTM)
- 0.71×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.4×
- Earnings yield
- -998.45%
- Free cash flow yield
- -670.07%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -290.40%
- Return on assets
- -238.06%
- Return on invested capital
- -210.04%
Financial health
- Debt / equity
- 0×
- Current ratio
- 5.38×
- Altman Z-score
- -20.27
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 200.86K USD | 337.49K USD | 408.03K USD | 435.2K USD | 681.61K USD |
| Gross profit | −200.86K USD | −337.49K USD | −408.03K USD | −435.2K USD | −681.61K USD |
| Research and development | 2.78M USD | 2.84M USD | 7.25M USD | 8.03M USD | 4.79M USD |
| Selling, general, and administrative | 5.79M USD | 6.45M USD | 8.79M USD | 11.5M USD | 20.47M USD |
| Operating expenses | 8.57M USD | 9.29M USD | 16.04M USD | 19.53M USD | 25.26M USD |
| Interest income | — | 219 USD | — | 5.25 USD | 10.32 USD |
| Interest expense | 106 USD | — | 3.71K USD | 5.25K USD | 10.32K USD |
| Depreciation and amortization | 200.86K USD | 337.49K USD | 408.03K USD | 435.2K USD | 681.61K USD |
| Operating income | −8.77M USD | −9.63M USD | −16.45M USD | −19.96M USD | −25.94M USD |
| Net income | −12.13M USD | −9.57M USD | −17.29K USD | −18.5M USD | −48.98M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 44%
- 4 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -5392.81%
- 9 comparable reports
- Latest EPS result
- -0.76
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
4 ratingsLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Recent analyst actions
ENVB news
Corporate actions
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Apr 23, 2008 | $0.021Irregular | Apr 15, 2008 | — |
Ex-dividend Apr 23, 2008
$0.021
Irregular
Record Apr 15, 2008
ENVB peers
ETFs holding ENVB
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research ENVBresearch.disclaimer